Supplementary Materials

Supplementary Material for:

α-Enolase–binding peptide enhances drug delivery efficiency and therapeutic efficacy against colorectal cancer

Chien-Hsun Wu, Yi-Huei Kuo, Ruey-Long Hong, Han-Chung Wu*

*Corresponding author. E-mail: hcw0928{at}gate.sinica.edu.tw

Published 3 June 2015, Sci. Transl. Med. 7, 290ra91 (2015)
DOI: 10.1126/scitranslmed.aaa9391

This PDF file includes:

  • Materials and Methods
  • Fig. S1. In vitro panning and identification of phages that bind to hCRC.
  • Fig. S2. In vivo validation of the tumor-homing abilities of selected phage clones.
  • Fig. S3. Distribution of tumor-targeting and control phage in liver, kidney, and spleen.
  • Fig. S4. Competitive tumor-homing assay with selected phage and synthetic peptides.
  • Fig. S5. Binding of hCRC-targeted phage to carcinoma cell lines.
  • Fig. S6. Cytotoxicity profiles of different anticancer drugs in HCT116 cells.
  • Fig. S7. Schematic diagram showing the synthesis of peptide-targeted nanoparticles.
  • Fig. S8. Targeted delivery of liposomal drug to hCRC cells.
  • Fig. S9. Cytotoxicity of empty liposomes with or without pHCT74 peptide conjugation.
  • Fig. S10. Pharmacokinetics and tissue distribution of liposomal drugs.
  • Fig. S11. Tissue distribution studies with different formulations of liposomal drugs.
  • Fig. S12. Correlation between the binding of HCT74 phage and ENO1 expression.
  • References (42, 43)

[Download PDF]